Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback